Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.

Hossein Borghaei,Scott N. Gettinger,Everett E. Vokes,Laura Q.M. Chow,Marco Angelo Burgio,Javier de Castro-Carpeño,Adam Pluzanski,Oscar Arrieta,Osvaldo Arén Frontera,Rita Chiari,Charles Butts,Joanna Wojcik-Tomaszewska,Bruno Coudert,Marina Chiara Garassino,Neal Ready,Enriqueta Felip,Miriam Alonso García,David M. Waterhouse,Manuel Domine,Fabrice Barlesi,Scott J. Antonia,Markus Wohlleber,David E. Gerber,Grzegorz Czyzewicz,David R. Spigel,Lucio Crinò,Wilfried Enst Erich Eberhardt,Ang Li,Sathiya Marimuthu,Julie R. Brahmer

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.

2021

PURPOSEImmunotherapy has revolutionized the treatment of advanced non–small-cell lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab showed an improvement in o...

Keywords:

Internal medicine
Oncology
Docetaxel
Nivolumab
Lung cancer
non small cell
Checkmate
phase iii trials
Medicine
previously treated

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations